



June 11, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of U.S. FDA approval for the Company's Albendazole Tablets USP, 200 mg, to market a generic equivalent of Albenza® Tablets, 200 mg, of Impax Laboratories Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For LUPIN LIMITED

**RAJVARDH
AN VISHNU
SATAM**

Digitally signed by RAJVARDHAN VISHNU
SATAM
DN: c=IN, o=Personal, postalCode=400062,
st=Maharashtra,
2.5.4.20=c19d8ef961d9f659e973a093a4d3
924b2532eb2f496ea7e2abc74700f5375b7
*,
serialNumber=df8ebe60a8c796663c738e
a25bfa0b475d199726cd67a2f09c42427
71b2a, cn=RAJVARDHAN VISHNU SATAM
Date: 2020.06.11 15:54:29 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl- : a/a.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin Receives Approval for Albendazole Tablets USP

Mumbai, Baltimore, June 11, 2020: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Albenza® Tablets, 200 mg, of Impax Laboratories Inc.

Albendazole Tablets USP, 200 mg, are an anthelmintic drug indicated for treatment of:

- Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm
- Cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm

Albendazole Tablets USP (RLD: Albenza®) had an annual sales of approximately USD 34 million in the U.S. (IQVIA MAT April 2020).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra Head – Investor Relations and Corporate Communications Email: arvindbothra@lupin.com Tel: +91 22 6640 8237	Manjira Sharma General Manager – Corporate Communications Email: manjirasharma@lupin.com Tel: +91 22 6640 2532
--	---

****Safe Harbor Statement***

Albenza® is a registered trademark of GlaxoSmithKline LLC Limited.